Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

the standard of care. The study found:

-- Up to 81 percent of those patients treated with R1626 1500 mg (twice-

daily) + PEGASYS + COPEGUS had an undetectable HCV viral load by week

four (mean reduction of 5.2 log10 IU/mL)

-- ALT, a liver enzyme, normalized in approximately 50 percent of patients

in R1626 treatment groups

-- Most reported adverse events were mild to moderate. Dose dependent,

reversible grade four neutropenia was observed in the R1626 arms (36

percent in patients receiving R1626 1500 mg + PEGASYS + COPEGUS), and

was the main reason for dose reduction and discontinuation

Lack of Resistance

According to a second presentation at the conference, resistance to R1626 was not identified following intensive testing for either two weeks of treatment with R1626 as monotherapy, or in patients treated with R1626 for four weeks in combination with the standard of care. These findings suggest that there is a high barrier to the development of resistance to R1626 in vivo.

Start of Phase IIb Trial

R1626 is being progressed into Phase IIb study, called POLI 1, to further investigate the new treatment regimens of R1626, in combination with standard or lower dose of PEGASYS and standard dose of COPEGUS. This Phase IIb trial is now open and enrolling patients in eight countries, including the United States. More information about R1626 and the clinical studies can be found on http://www.roche-trials.com.

"As a clinician, I am excited by the high rates of viral negativity that were observed after four weeks of treatment with R1626 in combination with the standard of care. The design of the Phase IIb study should enable us to find the doses of R1626, PEGASYS and COPEGUS that achieve the appropriate balance between safety and efficacy," said Dr. David Nelson, Director of Hepatology and Liver Transplantation at the
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014 /CNW Telbec/ - Ergoresearch Ltd ("Ergoresearch" ... for accelerated growth in terms of sales and profitability. ... $17,862,341. Net income amounted to $1,230,153. The EBITDA reached ... time in the Company,s history. With the ... forces of its subsidiaries, merging in September 2014 Clinique ...
(Date:10/31/2014)... 2014 Research ... of the  "Process Validation in the US and ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,Key topics to ... Approach to Process Validation for Pharmaceutical and Biopharmaceutical ... FDA Process Validation Guidance EU Process ...
(Date:10/31/2014)... 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... , Isis Pharmaceuticals, Third Quarter 2014 Financial Results and ... 11:30 a.m. ET / 8:30 a.m. PTWhere: , ... Simply log onto our website listed above. If you ... replay of the webcast will be available for a ...
Breaking Medicine Technology:Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 2Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 3Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 4Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 5Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3
... Jan. 19, 2012 /PRNewswire/ --  Terumo Cardiovascular Systems announced ... with LAAx, Inc. to distribute the TigerPaw® System II, ... The TigerPaw System II is indicated ... visualization, in conjunction with other open cardiac procedures.  It ...
... SAN DIEGO, Jan. 19, 2012  Neurocrine Biosciences, Inc. (Nasdaq: ... an underwritten public offering of 9,500,000 shares of its ... $8.10 per share. The gross proceeds to Neurocrine from ... other offering expenses payable by Neurocrine, are expected to ...
Cached Medicine Technology:Terumo Cardiovascular Systems Becomes Exclusive U.S. Distributor for TigerPaw® System II, Left Atrial Appendage Closure Device 2Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock 2Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock 3
(Date:10/31/2014)... 31, 2014 (HealthDay News) -- Sleep apnea may make it ... you parked your car or left your house keys, a ... sleep apnea showed that this ability -- called spatial memory ... (REM) sleep, even when other stages of sleep weren,t affected. ... dreams typically occur. "We,ve shown for the first time ...
(Date:10/31/2014)... say that either they or a family member have ... latest issue of The Gerontological Society of America,s ... which goes on to show that Americans strongly support ... end-of-life health care wishes. , This PP&AR , ... features 12 articles that present new ways of understanding ...
(Date:10/31/2014)... New York (PRWEB) October 31, 2014 ... Mineola Eye in Garden City, Long Island and the ... to their medical staff, according to North Shore Eye ... is the Emeritus Acting Chairman of the Department of ... and successful practice in Garden City for more than ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 FindSurrogateMother.com ... most remarkable gifts of life — building a family ... extraordinary surrogate mothers and donors with hopeful intended parents ... unforeseen circumstances. , It’s a collective aptitude of surrogate ... surrogacy lawyers, and fertility clinics that help provide these ...
(Date:10/31/2014)... 31, 2014 BCC Research ( http://www.bccresearch.com ) ... QUALITY MARKET , the U.S. indoor air quality (IAQ) market ... a compound annual growth rate (CAGR) of 7% over the ... grow at a CAGR of 7.4%. , Since 2012, ... mold, the outbreak of infectious diseases such as bird flu ...
Breaking Medicine News(10 mins):Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Advance directives can benefit patients, families, and health care system 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 2Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 3
... A study was conducted by Nathan Thielman, M.D, Duke University ... effective in preventing HIV infections than those which charge a ... testing center and is therefore a very efficient method. ... free testing was conducted by The Duke researchers. Before that ...
... Plans have been announced by the Indian Government to ... which will highlight the achievements of Indian Scientists, //in ... science. The name of the new initiative of the ... for producing a one-hour film and 15 two-minute shorts ...
... most common cancer next to breast cancer in women and ... of cervical cancer would help in early treatment //and help ... cytologic screening test known as Pap smear test is used ... state and could detect early diagnosis. Women above the age ...
... have committed suicide five months ago using a lethal dose of ... degenerative disease// which made her life very traumatic and she had ... to escape from her traumatic pain so she went to Dignitas ... Irwin and Jessica Reid. ,Mrs. Jessica Reid who accompanied ...
... Bio-functional garments like stockings with aloe vera, T-shirts with ... been developed as the textile industry takes its cue ... garments an additional function in addition to keeping the ... their promises is a contentious matter. Experts also fear ...
... bond exists among siblings, even though they compete with each ... parents. The relationship which exists between siblings is very // ... do not welcome the birth of a new baby in ... among siblings. Their relationship has become more like partnerships, partly ...
Cached Medicine News:Health News:Free HIV Tests Brings Crowd to the Testing Centers 2Health News:Scented Garments Hit The Market 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: